A diabetes patient’s ambivalence about changing their diet or taking their insulin can stand between successful management of their disease and a further escalation that could lead to blindness, limb removal, or even death.
That’s where motivational interviewing makes a difference, says Maureen Hennessey, PhD, senior vice president and director of quality and population health solutions, and Elizabeth Oyekan, PharmD, senior director of quality and population health solutions, at New York-based Precision for Value. The company consults with pharmaceutical and life science clients in demonstrating the value and outcomes of their medical products.
Hennessey and Oyekan discussed how motivational interviewing can improve patient outcomes at the Academy of Managed Care Pharmacy Managed Care and Specialty Pharmacy Annual Meeting, which took place in Boston April 23 to 26.
Hennessey describes motivational interviewing as a patient-centric style of communication that helps to elicit and motivate change. Motivational interviewing strategies are more collaborative than coercive or combative and more supportive than directive, she adds.
If, for example, a patient with diabetes typically eats potatoes for dinner every night, that can interfere with their diabetes treatment plan. Rather than arguing with a patient and telling them they shouldn’t eat potatoes, motivational interviewing techniques can help determine their willingness to eat a smaller portion size or eat potatoes less often, says Hennessey.
She says there are four steps of motivational interviewing, which include:
Oyekan says compassion and empathy are key to the practice of motivational interviewing.
Exercising both is helpful when determining why a patient isn’t adhering to treatment recommendations, such as failing to take their medications, says Hennessey.
Asking a patient to tell you more about why they’re not taking their medications is helpful, says Hennessey.
She shared the example of a male patient with diabetes who didn’t take his medications. With this patient, his father had a negative outcome as a result of his diabetes medications. The patient then learned that there were new, more effective medications available.
Healthcare professionals first need to understand where the patient is coming from, and then they need to ask for permission to educate them about new treatments, says Hennessey, noting that asking for permission to provide that information is key. It also gives the patient a collaborative stance from which to get more engaged in their own treatment plan.
In this second part of a two-part podcast episode, Managed Healthcare Executive's Managing Editor Peter Wehrwein spoke with CeCi Connolly and Margaret "Meg" Murray about Medicare Advantage utilization and challenges, highlighting proposed CMS payment cuts and prior authorization issues.
Listen
New approvals this week include a $4.25 million gene therapy, a drug that treats hypertension in a new way, a nonsteroidal drug for Duchenne, and an oral drug for aggressive leukemia. The agency has set an action date for resubmitted Lymphir in rare skin cancer, and Celltrion has launched Zymfentra, a subcutaneous form of infliximab.
Read More
In this first part of a two-part podcast episode, Managed Healthcare Executive's Managing Editor Peter Wehrwein kicks off our new podcast series "DC Roundtable," with guests Margaret "Meg" Murray, CEO of the Association of Community Affiliated Plans, and member of MHE's Editorial Advisory Board, and CeCi Connolly, president and CEO of the Alliance of Community Health Plans, for a discussion on healthcare policy issues.
Listen